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(12.0%), but the most frequent ADR was dyskinesia (11.5%). Serious
ADRs and ADRs leading to discontinuation were infrequent and occurred
in 10 (2.6%) and 11 (2.8%) pts, respectively.
The OFF time reduction was maintained over 1 year, and the mean
change in OFF time from the DB baseline was -106.68 minutes at
28 weeks of the OL part, and it was -101.89 minutes at 52 weeks. Of note,
when switched from placebo to 50 mg of OPC, the OFF time sharply
decreased.
Conclusions: When a fixed 50 mg dose of OPC administered with a
varying dose of L-dopa/DCI or anti-PD drugs to Japanese PD pts with
end-of dose motor fluctuation, OPC was well tolerated for 1 year. Addi-
tionally, OPC had a lasting effect with a stable OFF time reduction.
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Safety of Gocovri in Clinical Practice: One-year Post-launch
Pharmacovigilance Data
C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San
Francisco, CA, USA)
Objective: To assess the real-world safety profile of Gocovri® (amanta-
dine) extended release capsules one year post-launch.
Background: Gocovri received FDA approval in August 2017 for dys-
kinesia in Parkinson’s disease (PD), with full commercial launch in
January 2018. Gocovri is dispensed through specialty pharmacies whose
representatives contact patients by phone on a monthly basis. All potential
adverse events (AEs) reported during these calls are considered solicited
and entered into a database.
Methods: First-year post-launch safety reporting for Gocovri was com-
pared with the safety reporting in the phase 3 clinical trials.
Results: Post-launch adverse event (AE) rates were comparable to, and
generally less than, AE rates in phase 3 studies, with Hallucination the
most frequently reported (17% post-launch vs 21% phase 3). The post-
launch hallucination rate for Gocovri is consistent with the 15% rate esti-
mated for immediate release amantadine in an authoritative review
(Parkes, 1981). Six MedDRA AE terms were reported at ≥3% post-launch
that had lower rates in phase 3, 2 PD related (Balance disorder 6%;
Tremor 5%), 3 relating to overall energy/strength (Fatigue 7%, Somno-
lence 5%, Asthenia 3%) and 1 nonspecific (Feel Abnormal 3%). Clinically
relevant AEs, observed at <3% in phase 3, included, Delusions, Paranoia,
Suicidality, and Apathy; post-launch rates were 1, 0.4, 0.2, and 0.1%,
respectively. No post-launch AEs of neuroleptic malignant-like syndrome
were reported. Fatalities in phase 3 were too few to provide a basis for
comparison, but post-launch rates were consistent with literature-reported
rates in PD. Most post-launch AEs showed an age-event relationship and
were experienced by patients receiving 274 mg of Gocovri, irrespective of
age. Preliminary investigations did not reveal any conspicuous associa-
tions between specific AEs and medical history or concomitant
medications.
Conclusions: Post-launch AEs closely parallel the AE profile from
phase 3. This may be due in part to frequent contact between specialty
pharmacy and patient. The association between AE rates and age high-
lights the importance of dose adjustment for patients with age-related renal
impairment and raises the possibility of other factors contributing to
reduced tolerability with age. Dosing at <274 mg should be considered in
patients who may be at heightened risk for AEs.
214
Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect
on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease
I. Taravini, G. Gomez, L. Tribbia, A. Cura, R. Rivero, M. Bernardi,
J. Ferrario, B. Baldi-Coronel, O. Gershanik, E. Gatto
(Gualeguaychú, Argentina)
Objective: We set to investigate the possible neuroprotective effect of
yerba mate (YM) consumption on dopaminergic neurons in a mice model
of Parkinson’s disease (PD).
Background: The motor symptoms of PD mainly emerge from the
gradual degeneration and loss of dopamine neurons within the substantia
nigra. Novel treatment approaches are needed as there is no current pre-
ventive therapy for PD. However, an inverse association was found
between coffee intake or smoking and the occurrence of PD. Likewise, a
case-control study revealed that consumption of ‘mate’ also has an inverse
association with the risk of developing PD. Furthermore, we have recently
shown that YM favors survival and growth of dopaminergic neurons in
culture. Mate is an infusion from the plant Ilex paraguariensis (popularly
known as yerba mate) widely consumed in several South American and
Mediterranean countries. This infusion contains bioactive phenolic com-
pounds with strong antioxidant and anti-inflammatory properties.
Methods: The extract of YM was obtained by ‘cebada simulada’, an
extraction method that emulates the way it is commonly consumed and
the main bioactive compounds (caffeine, theobromine, chlorogenic acid
and rutin) were quantified by HPLC. A partial degeneration of dopaminer-
gic neurons, as an early model of PD, was induced by a 6-OHDA injection
into the striatum of wild type mice. Animals received water (control) or
‘mate’ as their only source of fluid. Different periods of YM administra-
tion and concentrations were evaluated. During the treatment, locomotor
activity was evaluated in open field (OF) sessions, and after sacrifice, tyro-
sine hydroxylase (TH) immunohistochemistry was performed to evaluate
the degree of dopaminergic denervation.
Results: The infusion of YM was well accepted by the animals. Mice
that drank mate showed increased locomotor behavior compared to con-
trols during the OF sessions. The denervation protocol we used induced a
lesion degree ranging from 31 to 57%. Mice receiving a YM treatment for
4 months, after the injury with 6-OHDA, had a 12% higher density of
dopaminergic fibers remaining in the striatum than control mice.
Conclusions: These results provide further evidence on the beneficial
properties of YM and could lead to the development of novel preventive
therapeutic interventions using YM in association with the most com-
monly used drugs to treat PD.
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Short term use of bromocriptine for treatment of Parkinson’s disease
during pregnancy
D. Taylor, P. LeWitt (West Bloomfield, MI, USA)
Objective: Few reports describe experience with treatment of
Parkinson’s disease [PD] during pregnancy. About 5% of the population
with PD are young onset (onset prior to 40 yrs); of these < 50% are
female. [1] The incidence of pregnancy in this population seems to be very
low, and sharing the experience of treating a patient with PD through a
pregnancy is important.
Background: There are few reports as to the safety and efficacy of the
use of dopaminergic therapies for PD in pregnancy. The limited number
of cases prevents valid study as to potential outcomes. Many of the case
reports focus on the outcomes of the patient’s status, with escalation of
PD during the pregnancy often noted. [2,3] Recognition of safe treatment
options is needed for best control of patients through a pregnancy. Bromo-
criptine is an ergot-derived dopamine agonist [EDDA]. This class of medi-
cations has been recognized as leading to valvular heart disease [4];
bromocriptine, while considered safe for use during pregnancy, has been
shown to impart the risk for a dose-related cardiac valve thickening.
[5] Short-term use is less likely to cause structural valvular changes. Use
of a related EDDA during pregnancy, cabergoline, has been reported as
beneficial for symptom control without long-term complications. [6]
Methods: A 40 year old patient with PD presented to our clinic
reporting that she was pregnant. Treatment included pramipexole, 0.25 mg
TID, and carbidopa/levodopa 25/100, 1 TID, at that date. At 8 weeks ges-
tation, she stopped all of her PD medications due to concern about poten-
tial fetal risk. Her PD symptoms (tremor, rigidity, bradykinesia) escalated;
at 11 weeks she restarted carbidopa/levodopa on the advice of her obstetri-
cian. At 16 weeks, she developed wearing off and bromocriptine was
started in an effort to ease the motor fluctuations.
Results: The patient underwent cesarean section at 40 weeks and was
delivered of a robust male infant with Apgar scores of 9 and 10 at 1 and
5 minutes. Following her delivery, she weaned the bromocriptine.
Conclusions: Pregnancy in patients with PD is an infrequent occur-
rence, due to the rare incidence of PD in women of child bearing age.
Recognition that this can occur and knowledge of the treatment options is
needed. While bromocriptine is not ideal for long-term use in patients with
PD due to idiosyncratic risk for valvular heart disease, short-term use dur-
ing pregnancy may provide significant symptomatic benefit.
References: 1. Golbe, LI. Pregnancy and Movement Disorders. Neurol
Clin 1994;12:497-508. 2. Hagell P, Odin P, Vinge E. Pregnancy in
Parkinson’s Disease: A Review of the Literature and a Case Report. Mov
Disord. 1998;13(1):34-38. 3. Shulman LM, Minagar A, Weiner WJ. Brief
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